-
Mashup Score: 92023 IKCS: North America to feature three special awards - Kidney Cancer Association - 6 month(s) ago
The 2023 International Kidney Cancer Symposium: North America will feature three special awards honoring standout members of the kidney cancer community.
Source: www.kidneycancer.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Home | KCJ - 7 month(s) ago
Aberrant hypoxia signaling orchestrates metabolic reprogramming in clear cell renal cell carcinoma to support glycogen and lipid accumulation.
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
LATEST: 👉Cytoreductive Nephrectomy for met-RCC in the Era of ICI 👉The Impact of Endogenous Retroviruses in ccRCC 👉Mechanisms of Palliative Care in Treatment of RCC 👉HIF Pathway Inhibition hold much promise 👉KCJ Journal Club Read More https://t.co/k1lvB97lVF #KidneyCancer https://t.co/IdzhXDL3t1
-
-
Mashup Score: 2Campbell RA et al Q2 2023 | KCJ - 10 month(s) ago
ABSTRACT Renal mass in a solitary kidney is a challenging clinical scenario and partial nephrectomy (PN) is generally prioritized. For tumors with high complexity, an in vivo approach with hypothermia is most often preferred at our center. Ex vivo PN is another option although results with this approach have varied and its utility in this setting is not well defined. We present the case of a…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
🚨Just In: Ex-Vivo Partial Nephrectomy in a Solitary Kidney. https://t.co/OIoGu6UU8E Award Winning surgical video: ⭕️https://t.co/Ux898Q7c9a @SCampbellMDPhD @rebeccampbell50 @martin_hofmann_ @Jason_yc_Lin @CleClinicUro @Jason_yc_Lin @APitaMD @AmerUrological @Uroweb @UroOnc https://t.co/1QmcLK7mH9
-
-
Mashup Score: 1Home | KCJ - 10 month(s) ago
× Subscription Sign Up Sign Up Feel free to choose as many as you like. Newsletter Print Copy of KCJ electronic KCJ Terms of Service * Agree to…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
LATEST: 👉Ex-Vivo PN in a Solitary Kidney 👉Robotic-assisted cPN for msRCC following IO 👉ASCO 2023 Kidney Cancer Roundup 👉 2023 ASCO Meeting Summary 👉ASCO 2023 - Recommended Abstracts 👉 KCJ Journal Club Read More👉 https://t.co/k1lvB97lVF https://t.co/fOt3wh40UB
-
-
Mashup Score: 2Home | KCJ - 1 year(s) ago
× Subscription Sign Up Sign Up Feel free to choose as many as you like. Newsletter Print Copy of KCJ electronic KCJ Terms of Service * Agree to…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
LATEST: - Management of Chromophobe RCC with NIVO+IPI -ICIs in RCC: Impact of Nutritional Status, Inflammation & Body Composition - Practice-Changing Cancer Trials at #GU23 #GU23 Meeting Summary #GU23 - Recommended Abstracts Read More👉 https://t.co/IyAAAhoVCX https://t.co/HpRRUgvCAP
-
-
Mashup Score: 1Ravindra et al Q1 2023 | KCJ - 1 year(s) ago
Submitted – October 18, 2022 | Revised December 4, 2022 Accepted – December 7, 2022 | | ePublished – December 31, 2022 https://doi.org/10.52733/KCJ21n1-r1 ABSTRACT Renal Cell Carcinoma (RCC) is among the most frequently…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
🚨Just in: Immune Checkpoint Inhibitors in RCC: Examining the Impact of Nutritional Status, Inflammation, & Body Composition by @virajmaster's team 👉https://t.co/gV58zvi26C https://t.co/VBaqWo3S8Q
-
-
Mashup Score: 1Ravindra et al Q1 2023 | KCJ - 1 year(s) ago
Submitted – Februray 14, 2023 | Revised March 9, 2023 | Revised Manuscript Accepted – March 15, 2023 | ePublished – March 30, 2023 https://doi.org/10.52733/KCJ21n1-a1 ABSTRACT Chromophobe renal cell carcinoma (chRCC) is a rare histologic…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
🚨JUST IN: CASE STUDY: Successful Management of Metastatic Chromophobe RCC with NIVO + IPI by @RohanGarjeMD team 📷 https://t.co/OKJw94YQ2Q #ChromophobeRCC #KidneyCancer #RCC https://t.co/jg6IDt3ql9
-
-
Mashup Score: 0SUBMIT MANUSCRIPT TO KCJ | KCJ - 1 year(s) ago
× Subscription Sign Up Sign Up Feel free to choose as many as you like. Newsletter Print Copy of KCJ electronic KCJ Terms of Service * Agree to…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
@KidneyCancerJ provides immediate #OpenAccess to make research & conference info freely available to ensure a global exchange of knowledge. #NoSubmissionFee Accessed by more than 25,000 HCPs worldwide. #ServingFor20Years 🚨 SUBMIT Your Manuscript: 👉https://t.co/H9Gw4wajOo https://t.co/jjKPLCUpnP
-
-
Mashup Score: 0EDITOR MEMO DEC 2022 | KCJ - 1 year(s) ago
Dear Colleagues, This year’s IKCS2022 Annual meeting offered a dynamic agenda unveiling the latest scientific advances and pivotal data from a broad spectrum of topics in kidney cancers, including a significant amount of emerging data on renal cell carcinoma. From early-phase clinical trials to updates on novel therapeutics, the sessions offered a unique opportunity to gauge progress on a…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
Editor's Memo Dissecting the Basis for the Adjuvant Therapy in #RenalCellCarcinoma - Robert A Figlin, MD 📕https://t.co/Ud82EuOlXb @CSCancerCare #KidneyCancer #IKCSNA22 https://t.co/lvWRlnz4bR
-
-
Mashup Score: 0Zhang et al Q4 2022 | KCJ - 1 year(s) ago
Submitted – October 18, 2022 | Revised December 4, 2022 Accepted – December 7, 2022 | | ePublished – December 31, 2022 https://doi.org/10.52733/KCJ20n4-r Benjamin T. Berger, MD1,*, Michael R. Harrison, MD1,2, Matthew K. Labriola, MD1,2 1) Department of Medicine, Duke University…
Source: kidney-cancer-journal.comCategories: Latest Headlines, UrologyTweet-
🚨JUST IN: Treatment of Recurrent Metastatic Renal Cell Carcinoma After Adjuvant Immunotherapy #KEYNOTE-564 Berger et al. @MattLabsMD @MRHarrisonMD 👉 https://t.co/pq4bFAPaUs #RenalCarcinoma #KidneyCancer #RCC https://t.co/2QV5EQNiFf
-
🥳Congratulations to special career awards recipients: 👏Dr. Nizar Tannir, 👏@PavlosMsaouel, 👏@uretericbud Read @KidneyCancer press release: https://t.co/pjWYpP4Jrk @IKCSNA23 @MDAndersonNews @FoxChaseCancer https://t.co/rgqUfeBBXG https://t.co/ooVcLmCJE1